Published in Gene Therapy Weekly, May 9th, 2002
Terms of the acquisition were not disclosed.
"This acquisition strengthens our position in serving the genetic screening market and provides a foundation for us to further our innovation in genetic screening products and services," said David Schwartz, president of Bio-Rad Laboratories. "Quantase has an excellent reputation for quality products and broad customer acceptance throughout the world."
The current market for newborn screening tests is estimated to be...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.